These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 27135211)
1. ANTERIOR CHAMBER FLARE DURING BEVACIZUMAB TREATMENT IN EYES WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION. Hautamäki A; Luoma A; Immonen I Retina; 2016 Nov; 36(11):2183-2190. PubMed ID: 27135211 [TBL] [Abstract][Full Text] [Related]
2. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500 [TBL] [Abstract][Full Text] [Related]
3. PREDICTING RESPONSE OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION TO BEVACIZUMAB BASED ON SPECTRALIS OPTICAL COHERENCE TOMOGRAPHY. Segal O; Barayev E; Nemet AY; Mimouni M Retina; 2016 Feb; 36(2):259-63. PubMed ID: 26200510 [TBL] [Abstract][Full Text] [Related]
4. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration]. Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687 [TBL] [Abstract][Full Text] [Related]
5. Prognosti implications of pigment epithelial detachment in bevacizumab (avastin)-treated eyes with age-related macular degeneration and choroidal neovascularization. Freeman WR; Kozak I; Yuson RM; Nigam N; Cheng L; Mojana F Retina; 2011 Oct; 31(9):1812-8. PubMed ID: 21866073 [TBL] [Abstract][Full Text] [Related]
6. Angiographic Cystoid Macular Edema and Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials. Shah N; Maguire MG; Martin DF; Shaffer J; Ying GS; Grunwald JE; Toth CA; Jaffe GJ; Daniel E; Ophthalmology; 2016 Apr; 123(4):858-64. PubMed ID: 26778329 [TBL] [Abstract][Full Text] [Related]
7. REFRACTORY INTRARETINAL OR SUBRETINAL FLUID IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL RANIZUBIMAB: Functional and Structural Outcome. Gianniou C; Dirani A; Jang L; Mantel I Retina; 2015 Jun; 35(6):1195-201. PubMed ID: 25650710 [TBL] [Abstract][Full Text] [Related]
8. Intravitreal anti-vascular endothelial growth factor for typical exudative age-related macular degeneration in eyes with good baseline visual acuity. Chang YS; Han JI; Yoo SJ; Lew YJ; Kim JH Korean J Ophthalmol; 2014 Dec; 28(6):466-72. PubMed ID: 25435749 [TBL] [Abstract][Full Text] [Related]
9. INFLUENCE OF VITREOMACULAR INTERFACE ON ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY USING TREAT AND EXTEND TREATMENT PROTOCOL FOR AGE-RELATED MACULAR DEGENERATION (VINTREX). Houston SK; Rayess N; Cohen MN; Ho AC; Regillo CD Retina; 2015 Sep; 35(9):1757-64. PubMed ID: 26110596 [TBL] [Abstract][Full Text] [Related]
10. Is There Any Difference between Ranibizumab and Aflibercept Injections in Terms of Inflammation Measured with Anterior Chamber Flare Levels in Age-Related Macular Degeneration Patients: A Comparative Study. Demirel S; Bilici S; Batıoğlu F; Özmert E Ophthalmic Res; 2016; 56(1):35-40. PubMed ID: 27027523 [TBL] [Abstract][Full Text] [Related]